HBM Holdings (HKG:2142) said China's National Medical Products Administration (NMPA), through its Centre for Drug Evaluation, has granted clearance for its Investigational New Drug application for the treatment of chronic obstructive pulmonary disease (COPD).
The drug inhibits the TSLP-mediated signaling pathway by blocking the interaction between TSLP and TSLP receptor, the filing added.